首页|瑞典精准医疗发展的成功实践与挑战

瑞典精准医疗发展的成功实践与挑战

扫码查看
不同国家在医疗领域的政策和实践差异是由各国的文化、社会结构、经济状况和政治体制等多方面因素所驱动.尽管国情不同,全球共同目标是一致的,那就是推动医疗领域的进步,以提供更好的医疗护理和治疗方案,最大程度地满足患者的需求.国际精准医疗联盟(ICPerMed)参与全球协作,旨在促进和支持个性化医疗的发展和应用.其中,瑞典作为ICPerMed的主要成员之一,展示了个性化医疗和精准医疗领域的巨大潜力.鉴于此,本研究拟对瑞典精准医疗体系架构的建立背景、实施过程以及现存问题进行综述.该项目的成功经验将为包括中国在内的其他国家精准医学的发展提供重要借鉴.同时,尽管取得了显著成就,瑞典精准医疗的发展依然面临许多不足和挑战,例如数据隐私、社会伦理,以及大规模基因测序成本较高等,这些都有待不断改进和创新以进一步推动个性化医疗领域的前进.
Successful Practices and Challenges in the Development of Precision Medicine in Sweden
Differences in policies and practices in the healthcare sector among various countries are driven by multifaceted factors such as culture,social structure,economic conditions and political systems.Despite varying national circumstances,the global shared objective remains consistent,that is to advance the healthcare sector to offer improved medical care and treatment solutions,cater exten-sively to patients'needs.International Consortium for Personalized Medicine(ICPerMed)engages in global collaborations aiming at fos-tering and supporting the development and application of personalized medicine.As a key member of ICPerMed,Sweden has showcased significant potential in the field of personalized and precision medicine.Hence,this study aims to review the establishment background,implementation processes,and existing issues within Sweden's precision medicine framework.The success experiences of this initiative will serve as valuable reference points for the development of precision medicine in other countries,including China.However,despite significant achievements,Sweden's precision medicine development encounters several shortcomings and challenges,such as data pri-vacy,social ethics and the high costs associated with large-scale genetic sequencing,all of which require continuous improvement and innovation to further propel advancements in the field of personalized healthcare.

ICPerMedPrecision medicineSweden

李梅钰、韩洞明、李建康、高雅、金鑫

展开 >

深圳华大生命科学研究院,广东 深圳 518083

中国科学院大学生命科学学院,北京 100049

国际精准医疗联盟 精准医疗 瑞典

国家重点研发计划重点专项中国-欧盟国际精准医疗领域合作支持计划(IC2PerMed)

[2021YFE0192400

2024

中国医药导刊
国家食品药品监督管理局信息中心

中国医药导刊

影响因子:1.408
ISSN:1009-0959
年,卷(期):2024.26(1)
  • 10